Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

AK MEDICAL HOLDINGS LIMITED
愛康醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1789)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by AK Medical Holdings Limited (the "**Company**" or "**AK Medical**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders (the "**Shareholder(s)**") of the Company and potential investors with updated information in relation to the latest business development of the Group.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that, the Group has reached a preliminary intention with overseas customers on 7 April 2026 for the continuous procurement of various units of equipment in the first half of 2026. On this basis, the two parties formally entered into a sales contract for one unit of equipment on 7 April 2026. The purchaser further expressed its intention to purchase one additional unit of equipment within this month. In addition, during the period from December 2025 to April 2026, the Group entered into a number of overseas sales contracts. A summary of such contracts is set out below:

Country	Date of Contract	Contracted Equipment	Quantity (Units)	Delivery Status
Country A in South Asia	December 2025	K3 Robotic System	1	Delivered
Country B in Central Asia	February 2026	K3+ Robotic System	2	Delivered
Country A in South Asia	April 2026	K3 Robotic System	1	Undelivered

K3 ROBOTIC SYSTEM

K3 Intelligent Surgical Robot ("**K3 Robotic System**") adopts a robotic arm fully independently developed by the Group, featuring a compact and refined design that requires no additional space in the operating room. During surgery, K3 Robotic System is stable and efficient, providing functions ranging from preoperative planning to intraoperative assistance in osteotomy and prediction of joint stability. It is designed to restore knee joint function while improving surgical precision and efficiency. Its unique design enables surgeons to perform osteotomy procedures with ease, further enhancing the smoothness and safety of the operation.

K3+ ROBOTIC SYSTEM

The K3+ Robotic System, a pioneering total joint surgical robot in China capable of performing revision surgeries, with indications covering treatment of hip, knee and unicompartmental knee, was approved for marketing by the National Medical Products Administration on 15 January 2026.

OVERSEAS BUSINESS

The Company has achieved significant growth in its international operations through the implementation of a dual-brand strategy of "AK + JRI". This approach leverages brand strength in mature markets while pursuing scale expansion in emerging markets. In 2025, AK Medical extended its commercial presence to more than 40 countries, with its joints business ranking 12th globally, establishing a widely recognised brand profile in the international market.

JRI, the Group's UK subsidiary, serves as a source of credit asset and technical expertise. In 2025, its joints products completed the transition of overseas regulatory registrations from the Medical Devices Directive (MDD) to the Medical Device Regulation (MDR). With stable operations, JRI possesses global academic resources and an extensive expert network, as well as a mature research and development ("**R&D**") system and established product standards. Its European brand enjoys premium positioning in emerging markets and also serves as a global R&D center for new technologies.

AK Medical's export brand targets emerging markets and has demonstrated strong growth potential. The strategy focuses on building brand recognition and enhancing customer loyalty, leveraging China's manufacturing efficiency and cost advantages, as well as cost-performance upgrades through 3D printing and robotics, to rapidly expand market presence. In addition, AK Medical is presently the only orthopedic group in China with CE certifications covering a comprehensive orthopedic product portfolio, including joints, spine and trauma products. High-end customized 3D-printed products for bone tumor and revision surgeries are exported overseas, effectively addressing the supply gap for premium product lines in emerging markets.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 8 April 2026

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Dr. Gao Wei as independent non-executive Directors.